Connect with us

Health and Wellness

The study found that many patients who lose weight with GLP-1 stop treatment too early

Published

on

Research indicates that many people taking GLP-1 for weight loss don’t follow the treatment regimen long enough to realize the specified results.

According to CNNan evaluation of medical health insurance claims released Tuesday found that the vast majority of people using Wegovy and other GLP-1 drugs – about 58% – discontinued treatment inside 12 weeks, which fell in need of a critical benchmark set by skilled organizations for re-evaluation clinical effectiveness of treatment.

Advertisement

Patients start with a low dose of medication and may progressively increase the dose over time until the goal dose is reached. However, the evaluation shows that over 30% of individuals quit after the primary 4 weeks of treatment before reaching the goal dose.

The study examined pharmaceutical and medical claims for about 170,000 people with Blue Cross Blue Shield insurance policy and who were prescribed GLP-1 medications for weight management between 2014 and 2023.

“These are drugs used long-term to treat chronic diseases,” explained Dr. Disha Narang, director of obesity medicine at Chicago’s Endeavor Health, who was not involved in the brand new study. “It’s definitely a marathon, not a sprint. And if we treat it as a sprint, I think patients will probably get off their medications faster.”

Additionally, people who stopped using the medications were significantly less optimistic about their advantages. Specifically, only about half of individuals who had used injectable weight-loss medications prior to now found them effective, compared with almost three-quarters of individuals who were actively using these therapies.

Advertisement

Side effects resembling nausea, vomiting, constipation and diarrhea, that are common at first, can even put people off. Data from Wegova’s longest clinical trial showed that 17% of individuals using the drug decided to stop participating within the study because of uncomfortable side effects.

The cost of GLP-1 drugs can also be a barrier, because the monthly supply may be around $1,000 or more. However, the evaluation only included people with insurance policy that covered prescriptions for weight-loss drugs. Although insurance plan co-pays can have influenced cost considerations, the individuals analyzed didn’t should pay out-of-pocket for treatment.

The Blue Cross Blue Shield trial results highlight the critical role that providers can play in helping patients adhere to GLP-1 treatment.

Patients who had fewer visits with their providers, in addition to those living in underserved regions with significant health disparities, were more prone to discontinue GLP-1 treatment earlier. Dr. Razia Hashmi, vp of clinical affairs for the Blue Cross Blue Shield Association, said each additional follow-up visit increases a patient’s likelihood of continuous treatment by 60%.

Advertisement

Featured Stories

Although most prescriptions were made by primary care physicians, those prescribed GLP-1 by endocrinologists or others with expertise in weight management were more prone to receive no less than 12 weeks of continuous treatment.

“General support services really make a difference – whether the person is managing lifestyle support, nutrition, diet and side effect management,” Hashmi said, adding that “health equity matters. Social factors that influence health – transportation, access to food, socioeconomic status – all make a difference too.”

Another recent report from Dandelion Health, a healthcare analytics company that used the electronic health records of nearly 17,000 people prescribed GLP-1 between 2019 and 2023, supports the idea that long-term treatment extends the advantages of the drugs.

As one in every of the primary reports to supply real data on the effectiveness of GLP-1, preliminary findings showed that people taking the drugs experienced a median weight lack of about 1.4% after three months, which progressively increased to a median of about 3% after a full 12 months of treatment .

Advertisement

Compared to a gaggle of individuals with similar clinical characteristics – closely matched on demographic aspects, treatment indicators resembling mean body mass index and incidence of diabetes, treatment history and incidence of related diseases – the evaluation showed that people taking GLP-1 they lost almost twice as much weight.

Although experts caution that the treatment process may vary for everyone, GLP-1 treatment can still produce significant results.

“Whether it’s an employer trying to make a decision or an individual patient trying to make a decision, it’s really important to understand the success factors,” Hashmi said. “We want the investment to pay off.”


Advertisement
This article was originally published on : thegrio.com

Health and Wellness

Can psychedelics help you drink less alcohol? Our new study aims to find out

Published

on

By

Psychhedels reminiscent of LSD and psilocybina (Active ingredient in magical mushrooms) is gaining increasingly more attention in psychiatry. Research suggests They can offer therapeutic advantages in conditions reminiscent of depression, anxiety, obsessive and compulsive disorders, dietary disorders and addiction.

Our research team Study whether N, N-Dimetytryptamine (DMT)Quickly acting psychedelic, can help people reduce alcohol consumption.

Alcohol is most frequently Incorrectly used substance in Great Britainpartly since it is legal, widely available and deeply rooted in social culture. While many individuals can enjoy alcohol sparselyIN significant number Fight to control their drinking. For these people, Excessive alcohol consumption It can lead to serious physical, mental and social consequences.

Advertisement

Traditional treatments don’t work for everybody, which is why we examine alternatives reminiscent of psychedelics, which may allow people to change their behavior in a single transformational experience.



DMT is Metabolized quickly within the body. When administered intravenousThe effects start almost immediately, often in a single to two minutes. However, these effects are short -lived, lasting only ten to 20 minutes.

Advertisement

Despite the short duration of many users, they describe this experience as very deep. They often report live visions, complex patterns and feeling in one other reality. In some cases, experience leads to a whole change in how they think, feel and perceive the world. For many, this experience is deeply significant and transformational.

But what happens within the brain presently and the way can it affect long -term behavior, reminiscent of a discount in alcohol consumption?



Neuroplasticity and addiction

Our team He is especially all for how psychedelics reminiscent of DMT can help within the context of addiction. One theory is that psychedelics can temporarily increase neuroplasticityBrain ability to create new neural connections. This temporary reinforcement can open a window of flexibility, enabling some people more open to change.

For someone who got stuck in a heavy drinking cycle, this increased plasticity can help them break the old habits and develop healthier behavior. Basically, it might probably offer the brain Opportunity for “again” Sam and disturbing unhealthy patterns underlying addiction.

Advertisement

https://www.youtube.com/watch?v=ys9fbb19ws0

We also deal with reward and brain motivation systems, which play a key role in addiction. These systems affect the behavior related to pleasure, including food, sex and alcohol.

In individuals with Alcohol consumption disorderThese systems turn out to be hypersensitive to alcohol guidelines, often on the expense of other satisfying experiences. Some early studies He suggests that psychedelics can help “reset” these paths. We test this theory to see if DMT can reduce alcohol consumption by re -calibrating the brain prize system.

To examine these possibilities, we designed a study with drinking heavy, who’re motivated to reduce alcohol consumption. Each participant undergoes a radical screening test to be sure that they’re suitable for testing, and all sessions are conducted in a highly controlled, clinical environment with doctors and experienced researchers supervising this process.

Advertisement

The study includes three visits to our UCL laboratory. We use through the first and third visit Functional imaging of magnetic resonance imaging (FMRI) to measure brain activity and observe how different areas of the brain interact.

During scans, participants watch emotionally engaging movies that provide a more natural way of testing brain response compared to abstract tasks. This helps us assess how DMT can affect the brain function in real, emotionally charged situations.

During the second visit, the participants are randomly assigned to receive DMT, placebo or non -pryshedel medicine (D-CykLoserina Or Lisers). It is believed that these subszymical substances are believed Promote neuroplasticity Without inducing full psychedelic effects of DMT.

. The test is double blind – Neither participants nor scientists know which substance is run. This helps to eliminate bias and ensures that the outcomes are as reliable as possible.

Advertisement

In addition, we measure changes in brain activity during infusion of the drug with electroencephalography (EEG). EEG tracks the brain electrical signals and may help us predict which participants will almost certainly use DMT.

Participants also perform various psychological assessments, including questionnaires and tasks that measure memory, attention, mood and decision making. These data will help us understand how changes in brain function can relate to changes in behavior related to drinking.

What can we hope to discover

We are still within the technique of collecting data, but we’re excited whether DMT can lead to a major reduction in alcohol consumption. As scientists, it’s crucial for us to remain objective and permit the evidence to conduct our conclusions. By maintaining a “blind” test, until all results can be found, we be sure that our arrangements are objective and reliable.

If DMT proves to be effective in helping people to reduce alcohol consumption, especially for many who struggled with other treatments, it might probably pave the best way to a new approach to addiction therapy. Even if the outcomes are ambiguous, they may proceed to provide precious insight into the potential role of psychedels within the treatment of addiction and open new possibilities of future research.

Advertisement

https://www.youtube.com/watch?v=pkr-jvglkng

It is very important to emphasize that these research takes place in a protected, controlled environment. Psychhedels are strong substances, and their effects could be unpredictable, especially outside the clinical settings. They usually are not a “magic ball” and usually are not suitable for everybody. The controlled setting allows us to examine our effects, while minimizing the chance for participants.

Having said that, we imagine in psychhedels offer a special opportunity To higher understand the brain and its ability to change. By examining how transformational experiences can affect behavior, we hope to contribute to the event of simpler treatment of addiction and other mental health conditions.

Advertisement

This article was originally published on : theconversation.com
Continue Reading

Health and Wellness

Tina Knowles reveals the diagnosis of breast cancer and reminds people not to “bend over mammograms”

Published

on

By

Tina Knowles reveals the diagnosis of breast cancer and reminds people not to

Ghettos

Advertisement

Tina Knowles revealed that she was fighting breast cancer. The 71-year-old learned that she had cancer in stage 1 in July 2024. She learned about her diagnosis at a time when she launched the Cécred hair care line along with her daughter Beyoncé.

“It is important not to slow down to your mammograms,” she said during an interview with people. The creator also revealed that she missed mammography. Task group of American preventive services recommended That women aged 40 to 74, who’re exposed to the average risk of breast cancer, receive mammography every 2 years, but you may also get one yr.

“I forgot that I did not go to the test for two years before I thought I did it,” she said – “Because Covid came, they called me and canceled and said, we would call you when we started testing again. I just thought that I did it. So you can’t play with it.”

Advertisement

Tina revealed a message about her meeting with breast cancer in her diary, which he published on April 22.

“I fought with whether I would share this journey [in the book] Because I’m very private. But I decided to share it because I think these are many lessons for other women – he says. “And I believe that as women sometimes we’re so busy and we’re so wrapped and running, but you’ve got to go to the test. Because if I did not get the test early, I mean, fascinated with what could occur to me.”

While the news of a loved one could be devastating, Knowles said that her daughters had a realistic response to listening to her diagnosis.

She said that Beyoncé “took it well, remaining positive, and I already felt her mind racing, focusing on this as a task with precision.” Tiny’s second child, Solange said: “Mom, we’ll deal with it.” Additionally, Kelly Rowland who’s close to the matriarch, and her niece Angie Beyinka was also at her side. “My girls have become my team,” she wrote in a newly published book.

Advertisement

Fortunately, the dressmaker underwent surgery last yr to remove the tumor, and also obtained breast reduction.

“I’m great,” she said. “Without cancer and incredibly blessed that God let me find him early.”

Knowles wants women to remember about regular research – key detection is essential.

“I didn’t know that there was stage 0. I could catch it at stage 0 if I didn’t miss my mammogram,” she said.

Advertisement

Mama Super Gwiazda also wants people to know you can undergo the difficult terror of health and proceed to go to the top: “I want to show people that you can go and continue to fly.”

Nowadays, the 71-year-old is doing and feels good.

“I’m healthier, I eat better, I lost weight,” she told people.

“I want to give people hope,” Knowles added. “What scares me now is not the best to use every day that I left in this life.”

Advertisement

This article was originally published on : www.essence.com
Continue Reading

Health and Wellness

President of HBCU will submit a request for a donor of organs in graduation

Published

on

By

Livingstone College, organ Donation, kidney


President HBCU prays that a member of his school community may also help him find an organ donor.

Dr. Anthony J. Davis, president of Livingstone College, has been fighting kidney failure for almost two years. Since the diagnosis, Davis has undergone almost 10 hours of dialysis treatment at night, and was also juggling the duties of institutions. During the last ceremony of starting Livingstone, May 3 revealed his tragic request for a donor of organs.

“When the Lord is a blessing, the enemy begins to play”, he shared Graduate class, on.

Advertisement

Davis stays involved in lifting the college and her body, despite his medical failures. He remains to be working on increasing registration and recruitment, remaining at the highest of his goals to lift Livingstone. His term also recorded a donation of two anonymous gifts price $ 10 million per school.

Describing his health journey, he also noticed that none of his members of the family was entitled to a match because of their different blood groups.

“I said, my children, what is happiness? They have a good mother’s appearance and her blood group,” he shared the group’s laughter.

His emotional speech also inspired graduates to beat obstacles that they might encounter in their lives. Davis also began the “Be my match” campaign to assist search. The “Be My Match” initiative encourages those in the HBCU Livcustone community and out of doors of it to get to know a living donor. Davis expressed the hope and faith that his public declaration concerning the need for a donor would cause his community to seek out a match.

Advertisement

Blacks are disproportionately affected by kidney disease. According to the National Institute of Health, the 2023 annual report showed that this demographic group Accounts 30% of all individuals with final kidney disease (ESKD). Black are also 4 times more exposed to death because of their ECOD than their white counterparts, because of which their ability to seek out a match is more essential than ever.

Bearing in mind these numbers, Davis hopes that his network will strengthen this campaign to the masses to assist the educator and supporter of HBCu save his life. When he finished his powerful and key message, the category of 2025 and Davis hope that in the subsequent era of their lives with latest prosperity.

)

Advertisement
This article was originally published on : www.blackenterprise.com
Continue Reading
Advertisement

OUR NEWSLETTER

Subscribe Us To Receive Our Latest News Directly In Your Inbox!

We don’t spam! Read our privacy policy for more info.

Trending